Literature DB >> 25066554

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry.

Benjamin A Steinberg1, Rosalia G Blanco2, Donna Ollis2, Sunghee Kim2, DaJuanicia N Holmes2, Peter R Kowey3, Gregg C Fonarow4, Jack Ansell5, Bernard Gersh6, Alan S Go7, Elaine Hylek8, Kenneth W Mahaffey9, Laine Thomas2, Paul Chang10, Eric D Peterson1, Jonathan P Piccini11.   

Abstract

BACKGROUND: Recent clinical trials have demonstrated the safety and efficacy of several non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF). However, there are limited data on their use and outcomes in routine clinical practice, particularly among patients newly diagnosed as having AF and patients with AF recently transitioned to a NOAC. METHODS/
DESIGN: ORBIT-AF II is a multicenter, national registry of patients with AF that is enrolling up to 15,000 newly diagnosed patients with AF and/or those with AF recently transitioned to a NOAC from 300 US outpatient practices. These patients will be followed for up to 2 years, including clinical status, outcomes (major adverse cardiovascular events, bleeding), and management of anticoagulation surrounding bleeding events. In addition, detailed data regarding the use of these agents in and around cardiac procedures, their complications, and management of such complications will be collected.
CONCLUSIONS: The ORBIT-AF II registry will provide valuable insights into the safety and effectiveness of NOACs used in AF in community practice settings.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25066554      PMCID: PMC4145241          DOI: 10.1016/j.ahj.2014.04.005

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  33 in total

1.  Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

Authors:  Dhanunjaya Lakkireddy; Yeruva Madhu Reddy; Luigi Di Biase; Subba Reddy Vanga; Pasquale Santangeli; Vijay Swarup; Rhea Pimentel; Moussa C Mansour; Andre D'Avila; Javier E Sanchez; J David Burkhardt; Fadi Chalhoub; Prasant Mohanty; James Coffey; Naushad Shaik; George Monir; Vivek Y Reddy; Jeremy Ruskin; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2012-02-01       Impact factor: 24.094

2.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

3.  Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program.

Authors:  Paul S Chan; William J Oetgen; Donna Buchanan; Kristi Mitchell; Fran F Fiocchi; Fengming Tang; Philip G Jones; Tracie Breeding; Duane Thrutchley; John S Rumsfeld; John A Spertus
Journal:  J Am Coll Cardiol       Date:  2010-06-29       Impact factor: 24.094

4.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF.

Authors:  Jonathan P Piccini; Elizabeth S Fraulo; Jack E Ansell; Gregg C Fonarow; Bernard J Gersh; Alan S Go; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Laine E Thomas; Melissa H Kong; Renato D Lopes; Roger M Mills; Eric D Peterson
Journal:  Am Heart J       Date:  2011-10       Impact factor: 4.749

5.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

6.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

7.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

8.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

9.  Linking inpatient clinical registry data to Medicare claims data using indirect identifiers.

Authors:  Bradley G Hammill; Adrian F Hernandez; Eric D Peterson; Gregg C Fonarow; Kevin A Schulman; Lesley H Curtis
Journal:  Am Heart J       Date:  2009-06       Impact factor: 4.749

10.  Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Authors:  Gregory Y H Lip; Torben Bjerregaard Larsen; Flemming Skjøth; Lars Hvilsted Rasmussen
Journal:  J Am Coll Cardiol       Date:  2012-05-09       Impact factor: 24.094

View more
  19 in total

Review 1.  Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Authors:  Boris Arbit; Jonathan C Hsu
Journal:  Clin Cardiol       Date:  2015-07-14       Impact factor: 2.882

2.  Bimodal distribution of atrial fibrillation burden in 3 distinct cohorts: What is 'paroxysmal' atrial fibrillation?

Authors:  Benjamin A Steinberg; Zhen Li; Peter Shrader; Derek S Chew; T Jared Bunch; Daniel B Mark; Yelena Nabutovsky; Rashmee U Shah; Melissa A Greiner; Jonathan P Piccini
Journal:  Am Heart J       Date:  2021-11-25       Impact factor: 4.749

3.  Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.

Authors:  Utibe R Essien; DaJuanicia N Holmes; Larry R Jackson; Gregg C Fonarow; Kenneth W Mahaffey; James A Reiffel; Benjamin A Steinberg; Larry A Allen; Paul S Chan; James V Freeman; Rosalia G Blanco; Karen S Pieper; Jonathan P Piccini; Eric D Peterson; Daniel E Singer
Journal:  JAMA Cardiol       Date:  2018-12-01       Impact factor: 14.676

4.  Machine learning does not improve upon traditional regression in predicting outcomes in atrial fibrillation: an analysis of the ORBIT-AF and GARFIELD-AF registries.

Authors:  Zak Loring; Suchit Mehrotra; Jonathan P Piccini; John Camm; David Carlson; Gregg C Fonarow; Keith A A Fox; Eric D Peterson; Karen Pieper; Ajay K Kakkar
Journal:  Europace       Date:  2020-11-01       Impact factor: 5.214

5.  Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation.

Authors:  Frederik Dalgaard; Rebecca North; Karen Pieper; Gregg C Fonarow; Peter R Kowey; Bernard J Gersh; Kenneth W Mahaffey; Sean Pokorney; Benjamin A Steinberg; Gerald Naccarrelli; Larry A Allen; James A Reiffel; Michael Ezekowitz; Daniel E Singer; Paul S Chan; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2020-01-07       Impact factor: 4.749

6.  Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions.

Authors:  Fatima Ali-Ahmed; Karen Pieper; Rebecca North; Larry A Allen; Paul S Chan; Michael D Ezekowitz; Gregg C Fonarow; James V Freeman; Alan S Go; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Gerald V Naccarelli; Sean D Pokorney; James A Reiffel; Daniel E Singer; Benjamin A Steinberg; Eric D Peterson; Jonathan P Piccini; Emily C O'Brien
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2020-10-01

7.  Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.

Authors:  Zak Loring; Peter Shrader; Larry A Allen; Rosalia Blanco; Paul S Chan; Michael D Ezekowitz; Gregg C Fonarow; James V Freeman; Bernard J Gersh; Kenneth W Mahaffey; Gerald V Naccarelli; Karen Pieper; James A Reiffel; Daniel E Singer; Benjamin A Steinberg; Laine E Thomas; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2019-11-08       Impact factor: 4.749

Review 8.  Anticoagulation in Heart Failure: a Review.

Authors:  Emily P Zeitler; Zubin J Eapen
Journal:  J Atr Fibrillation       Date:  2015-06-30

9.  Disease understanding in patients newly diagnosed with atrial fibrillation.

Authors:  Brystana G Kaufman; Sunghee Kim; Karen Pieper; Larry A Allen; Bernard J Gersh; Gerald V Naccarelli; Michael D Ezekowitz; Gregg C Fonarow; Kenneth W Mahaffey; Daniel E Singer; Paul S Chan; James V Freeman; Jack Ansell; Peter R Kowey; James A Rieffel; Jonathan Piccini; Eric Peterson; Emily C O'Brien
Journal:  Heart       Date:  2017-08-08       Impact factor: 5.994

10.  ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study).

Authors:  Özcan Başaran; Osman Beton; Volkan Doğan; Mehmet Tekinalp; Ahmet Çağrı Aykan; Ezgi Kalaycıoğlu; İsmail Bolat; Onur Taşar; Özgen Şafak; Macit Kalçık; Mehmet Yaman; İbrahim Altun; Mustafa Özcan Soylu; Cevat Kırma; Murat Biteker
Journal:  Anatol J Cardiol       Date:  2016-10       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.